Organización Mundial de la Salud. (‎2022)‎. Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [‎recombinante]‎ (‎Convidecia™)‎ contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022

The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. The COVID-19 vaccine tracker: Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development; Provides analysis and visualization for several COVID-19 vaccine candidate categories; Tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies and including Phase 4 registered as interventional studies; Provides links to published reports on safety, immunogenicity and efficacy data of the vaccine candidates; Includes information on key attributes of each vaccine candidate and Allows users to search for COVID-19 vaccines through various criteria such as vaccine platform, schedule of vaccination, route of administration, developer, trial phase and clinical endpoints. The database is updated regularly - twice a week (Tuesday and Friday, 17:00 CET)

CONVIDECIA is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2. It is administered as a single dose.

This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize the efficiency of assessment, review and authorizations of medical products. Vaccines are undoubtedly the most complex medical products to develop, from concept to a stage where sufficient evidence of quality, safety and efficacy are collected to provide an assurance that their use will provide more benefits than risks when used in the context of a public health emergency

COVID Reference 23 May 2021

COVID Reference 23 May 2021

Issue Brief no.8. January 18,2021 Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies, implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages

Februrar 2021

INFO Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)–mit Vektor-Impfstoff –

A collection of resources on Covid-19 vaccines, including frequently asked questions, continuing medical education, published research, and commentary.